All In MedTech

FDA Clearance Tracker · P950032

APLIGRAF (GRAFTSKIN)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: May 22, 1998 (this decision)Source: openFDAMethods & limitations

PMA

Decided

May 22, 1998

Approved (conversion)

Time to decision

961 days

Received Oct 4, 1995. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P950032
Device name
APLIGRAF (GRAFTSKIN)
Applicant location
Canton, MA
Received
Oct 4, 1995
Decided
May 22, 1998
Decision
Approved (conversion)
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
66 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MGR

FDA's approval statement

As written in FDA's record.

This device is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1 month duration and which have not adequately responded to conventional ulcer therapy.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MGR. The earliest in FDA's data is P900033, decided Mar 1, 1996.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Organogenesis, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.